CONCORDIA RX Trademark

Trademark Overview


On Thursday, May 16, 2024, a trademark application was filed for CONCORDIA RX with the United States Patent and Trademark Office. The USPTO has given the CONCORDIA RX trademark a serial number of 98553736. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, June 23, 2025. This trademark is owned by Concordia Pharmaceuticals Inc., S.à.r.L. The CONCORDIA RX trademark is filed in the Pharmaceutical Products category with the following description:

a full line of pharmaceuticals for the treatment of depression, malaria, benign prostatic hyperplasia, partial seizures in adults with epilepsy, heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)
concordia rx

General Information


Serial Number98553736
Word MarkCONCORDIA RX
Filing DateThursday, May 16, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateMonday, June 23, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of the stylized wording "CONCORDIA", with the prescription symbol "RX" forming the "R" in "CONCORDIA".
Goods and Servicesa full line of pharmaceuticals for the treatment of depression, malaria, benign prostatic hyperplasia, partial seizures in adults with epilepsy, heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 16, 2024
Primary Code005
First Use Anywhere DateTuesday, February 28, 2017
First Use In Commerce DateTuesday, February 28, 2017

Trademark Owner History


Party NameConcordia Pharmaceuticals Inc., S.à.r.L
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLuxembourg L-1610
LU

Trademark Events


Event DateEvent Description
Monday, November 18, 2024NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, May 16, 2024NEW APPLICATION ENTERED
Monday, November 18, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 2, 2024ASSIGNED TO EXAMINER
Sunday, December 22, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, December 22, 2024NON-FINAL ACTION WRITTEN
Sunday, December 22, 2024NON-FINAL ACTION E-MAILED
Tuesday, March 18, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, March 18, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, June 23, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 23, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, June 23, 2025TEAS/EMAIL CORRESPONDENCE ENTERED